Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

Rheumatology International

Volumn 32, Issue 3, 2012, Pages 601-606

  Sahebari, Maryam ^a   Rezaieyazdi, Zahra ^a   Nakhjavani, Mohammadreza J ^b   Hatef, Mohammadreza ^a   Mahmoudi, Mahmoud ^c   Akhlaghi, Saaid ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Interleukine 18(IL 18); Soluble Fas (CD95 Apo 1); Systemic lupus erythematosus

Indexed keywords

FAS ANTIGEN; INTERLEUKIN 18; PREDNISOLONE;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; FEMALE; HOSPITALIZATION; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REFERENCE VALUE;

ADOLESCENT; ADULT; ANTIGENS, CD95; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-18; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84863325101     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1633-9     Document Type: Article

References (26)

1. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J (2008) Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 17:371-375 (Pubitemid 351798710)
2. Sahin M, Aydintug O, Tunc SE, Tutkak H, Naziroǧlu M (2007) Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem 40:6-10 (Pubitemid 46014162)
3. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126-1129 (Pubitemid 27242300)
4. Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ (2006) Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res 297(7):329-332 (Pubitemid 41789818)
5. Alecu M, Coman G, Alecu S (2000-2001) Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38-39:83-88 (Pubitemid 36540018)
6. Courteny PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL (1999) Lymphocyte apoptosis in systemic lupus erythematosus, relationship with Fas expression, serum soluble FAS and diease activity. Lupus 8:508-513 (Pubitemid 29452562)
7. Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12:8-14 (Pubitemid 36172656)
8. Carroll HP, Paunovic V, Gadina M (2008) Crossed signals: the role of interlukin-15 and -18 in autoimmunity. Rheumatology 47:1269-1277
9. Boraschi D, Dinarello CA (2006) IL-18 in autoimmunity: review. Eur Cytokine Netw 17(4):224-252
10. Calvani N, Richards HB, Tucci M, Pannarale G, Silvester F (2004) Upregulation of IL-18 and predominance of Th1 immune response is a hallmark of lupus nephritis. Clin Xp Immunol 138:171-178 (Pubitemid 39279981)
11. Park MC, Park YB, Lee SK (2004) Elevated interlukin- 18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol 23:225-229 (Pubitemid 38812201)
12. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M (1997) Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17:3253-3258 (Pubitemid 27522278)
13. Kitaura H, Tatamiya M, Nagata N, Fujimura Y, Eguchi T, Yoshida N, Nakayama K (2006) IL-18 induces apoptosis of adherent bone marrow cells in TNF- a mediated osteoclast formation in synergy with IL-12. Immunol Lett 107:22-31 (Pubitemid 44332544)
14. Reddy P (2004) Interleukin-18: recent advances. Curr Opin Hematol 11:405-410 (Pubitemid 39491434)
15. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H (1996) Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 173:230-235 (Pubitemid 26381401)
16. Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JN (2007) Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset still's disease. Arthritis Rheum (Arthritis Care Res) 57: 1530-1538
17. Marín-Serrano E, Rodríguez-Ramos C, Díaz F, Martín-Herrera L, Girón-González JA (2006) Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat. 13:230-234
18. Nakae H, Zheng YJ, Wada H, Tajimi K, Endo S (2003) Involvement of IL-18 and soluble fas in patients with postoperative hepatic failure. Eur Surg Res 35:61-66 (Pubitemid 36407913)
19. El-Masry S, Lotfy M, Nasif WA, El-Kady IM, Al-Badrawy M (2007) Elevated serum level of interleukin (IL)-18, interferon (IFN)-gamma and soluble Fas in patients with pulmonary complications in tuberculosis. Acta Microbiol Immunol Hung 54:65-77 (Pubitemid 46993421)
20. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725
21. Dalboni MA, Sardenberg C, Andreoli MC, Watanabe R, Canziani ME, Santos BF, Liangos O, Jaber BL, Draibe S, Cendoroglo M (2003) Soluble FAS a novel marker of inflammation in uremia. Artif Organs 27:678-691
22. Sahebari M, hatef, Rezaiyeyazdi Z, Abbasi M, Abbasi B, Mahmoudi M (2010) Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in khorasan. Iran. Arch Iran Med 13:135-142
23. Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C (2009) Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol. doi: 10.1093/intimm/dxn142
24. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H (1999) Differential anti tumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforininduced tumor apoptosis, respectively. J Immunol 163:583-589 (Pubitemid 29328059)
25. Satoko I, Nobuhiro S, Yoshihiro I, Shigeatsu E (2005) A study of interleukin 18 and sFas in septic multiple organ dysfunction syndrome. J Iwate Med A 5:497-503
26. Mariño E, Cardier JE (2003) Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-a and Fas (CD95). Cytokine 22:142-148 (Pubitemid 36808760)